ADAM10 and cancer: Mutating the core cysteine residues in the PAN domain led to reduced expression of early growth response 1 (EGR1), as well as the metalloproteinases, A disintegrin and metalloprotease domain-containing protein 9 and 10 (ADAM9 and ADAM10), all of which were previously linked to increased adhesion and cancer progression including, hepatocellular carcinoma, and triple negative breast cancer via the AKT/NF-κB axis41–43.